The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

Analysts at Citi said that while the clinical hold impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously expected around 2029/2030, they believe the setback is minor, as it ...